Evidence map›Paper›PMID 36441482›Full record

ArticleRheumatology and therapy2023

Commentary on Cohen et al.: Role of Clinical Factors in Precision Medicine Test to Predict Nonresponse to TNFi Therapies in Rheumatoid Arthritis.

Stanley Cohen, Jeffrey R Curtis, Theodore Mellors, Lixia Zhang, Johanna B Withers, Alex Jones, Susan D Ghiassian, Viatcheslav R Akmaev

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Stanley CohenInternal Medicine, Rheumatology Division, Metroplex Clinical Research Center, Dallas, TX, USA.
Jeffrey R CurtisDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Theodore MellorsScipher Medicine Corporation, 221 Crescent St, Suite 103A, Waltham, MA, USA.
Lixia ZhangScipher Medicine Corporation, 221 Crescent St, Suite 103A, Waltham, MA, USA.
Johanna B WithersScipher Medicine Corporation, 221 Crescent St, Suite 103A, Waltham, MA, USA. johanna.withers@scipher.com.
Alex JonesScipher Medicine Corporation, 221 Crescent St, Suite 103A, Waltham, MA, USA.
Susan D GhiassianScipher Medicine Corporation, 221 Crescent St, Suite 103A, Waltham, MA, USA.
Viatcheslav R AkmaevScipher Medicine Corporation, 221 Crescent St, Suite 103A, Waltham, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 2021 study described the development and validation of a blood-based precision medicine test called the molecular signature response classifier (MSRC) that uses 23 features to identify rheumatoid arthritis (RA) patients who are likely nonresponders to tumor necrosis factor-α inhibitor (TNFi) therapy. Both the gene expression features and clinical components (sex, body mass index, patient global assessment, and anti-cyclic citrullinated protein) included in the MSRC were statistically significant contributors to MSRC results. In response to continued inquiries on this topic, we write this letter to provide additional insights into the contribution of clinical components to the MSRC on the Network-004 validation cohort.

Indexed as

Clinical assessmentsMolecular signature response classifierPrecision medicineRheumatoid arthritis

Identifiers

PMID36441482
PMCPMC9931968

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.